title: Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
abstract: Previous studies show that a recombinant modified vaccinia Ankara (MVA) virus expressing VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR -/-) against challenge. Follow up experiments indicated that passive transfer of antiserum, from MVA-VP2 immune donors to recipient mice 1h before challenge, conferred complete clinical protection and significantly reduced viraemia. These studies have been extended to determine the protective effect of MVA-VP2 vaccine-induced antiserum, when administered 48h before, or 48h after challenge. In addition, passive transfer of splenocytes was undertaken to assess if they confer any degree of immunity to immunologically naïve recipient mice. Thus, antisera and splenocytes were collected from groups of mice that had been vaccinated with MVA-VP2, or wild type MVA (MVA-wt), for passive immunisation of recipient mice. The latter were subsequently challenged with AHSV-4 (together with appropriate vaccinated or unvaccinated control animals) and protection was assessed by comparing clinical signs, lethality and viraemia between treated and control groups. All antiserum recipients showed high protection against disease (100% survival rates even in mice that were immunised 48h after challenge) and statistically significant reduction or viraemia in comparison with the control groups. The mouse group receiving splenocytes from MVA-VP2 vaccinates, showed only a 40% survival rate, with a small reduction in viraemia, compared to those mice that had received splenocytes from MVA-wt vaccinates. These results confirm the primarily humoral nature of protective immunity conferred by MVA-VP2 vaccination and show the potential of administering MVA-VP2 specific antiserum as an emergency treatment for AHSV.
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom.
authors: Eva
authors: E
authors: Calvo-Pinilla
authors: Centro de Investigación en Sanidad Animal, CISA-INIA, Valdeolmos, Madrid, Spain.
authors: Francisco
authors: F
authors: de la Poza
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom.
authors: Simon
authors: S
authors: Gubbins
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom.
authors: Peter Paul Clement
authors: PP
authors: Mertens
authors: Centro de Investigación en Sanidad Animal, CISA-INIA, Valdeolmos, Madrid, Spain.
authors: Javier
authors: J
authors: Ortego
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom. Electronic address: javier.castillo-olivares@pirbright.ac.uk.
authors: Javier
authors: J
authors: Castillo-Olivares
mesh_terms: D000355:African Horse Sickness / Q000276:immunology* / Q000517:prevention & control* / Q000628:therapy / Q000821:virology; D000356:African Horse Sickness Virus / Q000235:genetics / Q000276:immunology*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000276:immunology; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000276:immunology*; D036022:Capsid Proteins / Q000276:immunology*; D058501:Enzyme-Linked Immunospot Assay; D006736:Horses; D007116:Immunization, Passive; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D018345:Mice, Knockout; D053633:Receptor, Interferon alpha-beta / Q000235:genetics; D013154:Spleen / Q000166:cytology; D014765:Viral Vaccines / Q000276:immunology* / Q000627:therapeutic use; D014766:Viremia / Q000517:prevention & control
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; C442519:VP2 protein, African horse sickness virus; D014765:Viral Vaccines; D053633:Receptor, Interferon alpha-beta; D007371:Interferon-gamma
keywords: AHSV; African horse sickness; Humoral immunity; MVA-VP2; Passive immunisation; Protection
references: Virology. 1993 Oct;196(2):799-803
references: 7690505
references: J Virol. 2000 Aug;74(16):7651-5
references: 10906221
references: Arch Virol Suppl. 1998;14:177-202
references: 9785506
references: Trop Anim Health Prod. 1988 Nov;20(4):203-10
references: 3238767
references: Equine Vet J. 2013 Sep;45(5):604-7
references: 23294121
references: Vaccine. 2014 Jun 17;32(29):3670-4
references: 24837765
references: Vaccine. 2003 Dec 8;22(1):21-9
references: 14604567
references: Vet Res. 2004 Jul-Aug;35(4):445-66
references: 15236676
references: J Gen Virol. 2000 Apr;81(Pt 4):993-1000
references: 10725425
references: J Gen Virol. 2001 Oct;82(Pt 10):2415-2424
references: 11562535
references: PLoS One. 2009 Nov 12;4(11):e7790
references: 19915662
references: PLoS One. 2013 Apr 12;8(4):e60574
references: 23593251
references: Vaccine. 2009 Dec 11;28(2):437-45
references: 19857449
references: Vet Immunol Immunopathol. 2012 Mar 15;146(1):81-6
references: 22365333
references: Virology. 1996 Jun 1;220(1):219-22
references: 8659117
references: Vaccine. 2002 Jan 15;20(7-8):1079-88
references: 11803068
references: Vet Immunol Immunopathol. 2012 Sep 15;149(1-2):76-85
references: 22763149
references: Curr Gene Ther. 2008 Apr;8(2):97-120
references: 18393831
references: Clin Infect Dis. 2011 Jan 1;52(1):1-7
references: 21148512
references: Onderstepoort J Vet Res. 1999 Jun;66(2):139-44
references: 10486832
references: Virus Res. 2014 Feb 13;180:23-30
references: 24333835
references: PLoS One. 2011 Jan 26;6(1):e16503
references: 21298069
references: PLoS One. 2013;8(3):e57726
references: 23526949
references: PLoS One. 2013 Jul 23;8(7):e70197
references: 23894615
references: Immunology. 1984 Jul;52(3):403-10
references: 6086501
references: Vaccine. 2013 Sep 6;31(39):4223-30
references: 23746455
references: J Gen Virol. 1996 Jun;77 ( Pt 6):1211-21
references: 8683209
references: J Immunol. 2005 Jul 1;175(1):591-8
references: 15972696
references: Virology. 1995 Jul 10;210(2):391-9
references: 7542417
references: PLoS One. 2009 Jun 22;4(6):e5997
references: 19543394
references: Comp Immunol Microbiol Infect Dis. 1994 Aug-Nov;17(3-4):243-73
references: 8001348
references: Vaccine. 2013 Sep 6;31(39):4241-6
references: 23523410
references: Res Vet Sci. 1984 Jan;36(1):81-6
references: 6324311
references: J Virol. 2014 Mar;88(6):3527-47
references: 24403588